Cancer research has traditionally focused on DNA mutations and RNA changes, but a new study published in Precision Clinical Medicine challenges this narrow view. The study, authored by experts from renowned institutions, highlights the crucial role of altered protein modifications, or post-translational modifications (PTMs), in cancer development and progression.
The Power of Protein Modifications
Proteins are the cellular workhorses, and PTMs can rapidly alter their activity, stability, location, and interactions. These modifications are often rewired in cancer, leading to dysregulated signaling, metabolism, chromatin organization, immune evasion, and drug resistance. The study emphasizes that focusing on individual modifications or enzymes can be limiting, as it doesn't capture the complex regulatory network at play.
Unraveling the PTM Landscape
The review, titled "Protein modification systems as cancer biomarkers and therapeutic targets," identifies two key aspects of PTM dysregulation in cancer:
Direct Drivers: Individual PTMs can directly contribute to tumor initiation, metastasis, immune evasion, and therapeutic resistance. For instance, phosphorylation can amplify cancer-promoting signaling, while acetylation and methylation can reshape chromatin and transcription. Emerging modifications like lactylation, palmitoylation, and citrullination further expand our understanding of this regulatory landscape.
PTM Crosstalk: Different modifications can cooperate or compete on the same protein or pathway, creating a complex network. This crosstalk can stabilize malignant signaling, weaken tumor-suppressive programs, reprogram metabolism, and support immune checkpoint activity involving PD-1 and PD-L1. These combined PTM signatures may offer a more comprehensive understanding of patient heterogeneity compared to single molecular markers.
Beyond Genes: The Role of Protein Regulation
The authors argue that cancer should be viewed as a disease of altered protein regulation, not just altered genes. PTMs provide a dynamic and functional perspective on tumor cell state, complementing genomic and transcriptomic data. Analyzing PTM writers, erasers, readers, substrates, and modification sites as an integrated network can lead to improved biomarker discovery and the identification of targetable vulnerabilities associated with tumor progression.
Clinical Impact and Future Directions
The clinical implications of this research are far-reaching. PTM-based biomarkers could enhance early detection, molecular subtyping, prognosis, and therapy response prediction, especially when combined with advanced techniques like quantitative proteomics, spatial profiling, and machine learning. Examples cited include glycosylated alpha-fetoprotein (AFP), phosphorylated extracellular signal-regulated kinase (ERK), and deglycosylated PD-L1.
Therapeutic strategies related to PTMs are already in development, including kinase inhibitors, histone deacetylase (HDAC) inhibitors, bromodomain and extraterminal (BET) inhibitors, and epigenetic therapies. The study suggests that precision oncology might move away from single-marker testing towards system-level PTM maps, providing a more comprehensive understanding of tumor adaptability and potential intervention points.
In conclusion, this study emphasizes the importance of considering protein modifications as a crucial aspect of cancer biology. By unraveling the complex PTM landscape, researchers can unlock new insights into cancer mechanisms, improve biomarker discovery, and develop more effective therapeutic strategies.
